Homaira N; Daniels B; Pearson S; Jaffe A, 2020, 'Dispensing practices of fixed dose combination controller therapy for asthma in australian children and adolescents', International Journal of Environmental Research and Public Health, vol. 17, pp. 1 - 7, http://dx.doi.org/10.3390/ijerph17165645

Zheng D; Brett J; Daniels B; Buckley NA; Pearson SA; Schaffer AL, 2020, 'Potentially inappropriate benzodiazepine use in Australian adults: A population-based study (2014–2017)', Drug and Alcohol Review, vol. 39, pp. 575 - 582, http://dx.doi.org/10.1111/dar.13086

Favell DL; Tang M; Daniels B; Vajdic CM; Zoega H; Pearson SA, 2020, 'Capture of systemic anticancer medicines in pharmaceutical benefits scheme (PBS) data likely higher than previously reported', Public Health Research and Practice, vol. 30, http://dx.doi.org/10.17061/phrp3022013

Wu J; Dickinson S; Elgebaly Z; Blogg S; Heaney A; Soo Y; Daniels B; Weekes L, 2020, 'Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia', BMC Family Practice, vol. 21, pp. 85, http://dx.doi.org/10.1186/s12875-020-01158-1

Bruno C; Pearson SA; Daniels B; Buckley NA; Schaffer A; Zoega H, 2020, 'Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia', BMJ Quality and Safety, vol. 29, pp. 365 - 373, http://dx.doi.org/10.1136/bmjqs-2019-009897

Daniels B; Tervonen HE; Pearson SA, 2020, 'Identifying incident cancer cases in dispensing claims: A validation study using Australia's Repatriation Pharmaceutical Benefits Scheme (PBS) data', International Journal of Population Data Science, vol. 5, http://dx.doi.org/10.23889/ijpds.v5i1.1152

Daniels B; Pearson SA; Buckley NA; Bruno C; Zoega H, 2020, 'Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016', Therapeutic Advances in Gastroenterology, vol. 13, http://dx.doi.org/10.1177/1756284820913743

Falster MO; Charrier R; Pearson SA; Buckley NA; Daniels B, 2020, 'Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.14504

Brett J; Pearson SA; Daniels B; Wylie CE; Buckley NA, 2020, 'A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.14527

Daniels B; Luckett T; Holliday S; Liauw W; Lovell M; Phillips J; Rowett D; John TN; Tervonen H; Pearson SA, 2020, 'Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13408

Tang M; Schaffer A; Kiely BE; Daniels B; Simes RJ; Lee CK; Pearson SA, 2019, 'Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)', British Journal of Cancer, vol. 121, pp. 904 - 911, http://dx.doi.org/10.1038/s41416-019-0612-5

Daniels B; Kiely BE; Tang M; Tervonen H; Pearson SA, 2019, 'Trastuzumab use in older patients with HER2-positive metastatic breast cancer: Outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015)', BMC Cancer, vol. 19, http://dx.doi.org/10.1186/s12885-019-6126-y

Lord SJ; Kiely BE; Pearson SA; Daniels B; O'Connell DL; Beith J; Bulsara MK; Houssami N, 2019, 'Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: A population-based health record linkage study protocol', BMJ Open, vol. 9, http://dx.doi.org/10.1136/bmjopen-2018-026414

Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA, 2019, 'Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients', Pharmacoepidemiology and Drug Safety, http://dx.doi.org/10.1002/pds.4751

Brett J; Zoega H; Buckley NA; Daniels BJ; Elshaug AG; Pearson SA, 2018, 'Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia', BMC Health Services Research, vol. 18, pp. 1009, http://dx.doi.org/10.1186/s12913-018-3811-5

Tan SYS; O’Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM, 2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia-Pacific Journal of Clinical Oncology, vol. 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)', Breast Cancer Research and Treatment, vol. 171, pp. 151 - 159, http://dx.doi.org/10.1007/s10549-018-4804-0

Daniels B; Girosi F; Tervonen H; Kiely BE; Lord SJ; Houssami N; Pearson SA, 2018, 'Adherence to prescribing restrictions for her2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)', PLoS ONE, vol. 13, http://dx.doi.org/10.1371/journal.pone.0198152

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016)', Breast, vol. 38, pp. 7 - 13, http://dx.doi.org/10.1016/j.breast.2017.11.007

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, vol. 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025

Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA, 2018, 'Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: A national population-based observational study (2006-2014)', British Journal of Cancer, vol. 118, pp. 441 - 447, http://dx.doi.org/10.1038/bjc.2017.405

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, vol. 27, http://dx.doi.org/10.17061/phrp2751744

Brett J; Daniels B; Karanges EA; Buckley NA; Schneider C; Nassir A; McLachlan AJ; Pearson SA, 2017, 'Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study', British Journal of Clinical Pharmacology, vol. 83, pp. 2581 - 2588, http://dx.doi.org/10.1111/bcp.13369

Brett J; Karanges EA; Daniels B; Buckley NA; Schneider C; Nassir A; Zoega H; McLachlan AJ; Pearson SA, 2017, 'Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure', Australian and New Zealand Journal of Psychiatry, vol. 51, pp. 990 - 999, http://dx.doi.org/10.1177/0004867417721018

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv : an international journal of pathology, vol. 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5

Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA, 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, vol. 7, http://dx.doi.org/10.1136/bmjopen-2016-014439

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, vol. 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4

Vajdic CM; Mayson E; Dodds AJ; O'Brien T; Wilcox L; Nivison-Smith I; Le Marsney R; Daniels B; Ashton LJ; Tan J; Bilmon I; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2016, 'Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study', Biology of Blood and Marrow Transplantation, vol. 22, pp. 949 - 956, http://dx.doi.org/10.1016/j.bbmt.2016.01.027

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: The NSW poisons information centre experience, 2004-2014', Medical Journal of Australia, vol. 204, pp. 154.e1 - 154.e7, http://dx.doi.org/10.5694/mja15.00791

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014', The Medical journal of Australia, vol. 204, pp. 154

Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA, 2015, 'The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers', BMC Research Notes, vol. 8, http://dx.doi.org/10.1186/s13104-015-1616-8

Ward RL; Laaksonen MA; van Gool K; Pearson SA; Daniels B; Bastick P; Norman R; Hou C; Haywood P; Haas M, 2015, 'Cost of cancer care for patients undergoing chemotherapy: The elements of cancer care study', Asia-Pacific Journal of Clinical Oncology, vol. 11, pp. 178 - 186, http://dx.doi.org/10.1111/ajco.12354

Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA, 2015, 'Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy', Leukemia, vol. 29, pp. 441 - 447, http://dx.doi.org/10.1038/leu.2014.203

Blanch B; Daniels B; Litchfield M; Pearson SA, 2015, 'Looking forward and looking back: The balancing act in new drug user designs for pharmacoepidemiological research', Pharmacoepidemiology and Drug Safety, vol. 24, pp. 1117 - 1119, http://dx.doi.org/10.1002/pds.3848

Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM; Ashton L; Le Marsney R; Dodds A; Tan J; Bilmon I; Wilcox L; Nivison-Smith I; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; O'Brien T; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2014, 'Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study', Bone Marrow Transplantation, vol. 49, pp. 691 - 698, http://dx.doi.org/10.1038/bmt.2014.13

Couttas TA; Kain N; Daniels B; Lim XY; Shepherd C; Kril J; Pickford R; Li H; Garner B; Don AS, 2014, 'Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis', Acta Neuropathologica Communications, vol. 2, http://dx.doi.org/10.1186/2051-5960-2-9

Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2014, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, vol. 141, pp. 243 - 254, http://dx.doi.org/10.1007/s00432-014-1824-y

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, vol. 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Daniels B, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B, 2017, 'Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): an Australian whole-of-population cohort study', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management., 30 October 2017 - 01 November 2017

Daniels B, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', Montreal, QC, Canada, presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Daniels B, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', Gold Coast, QLD, presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Daniels B, 2016, 'Tracking trastuzumab (H) therapy in early- through late-stage HER2-positive breast cancer (HER2+BC) in Australia: A national, retrospective cohort study', Dublin, Ireland, presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 26 August 2016 - 29 August 2016

Daniels B, 2016, 'Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early- through late-stage HER2-positive breast cancer (HER2+BC)', Swansea, Wales, UK, presented at International Population Data Linkage Conference, Swansea, Wales, UK, 23 August 2016 - 26 August 2016

Daniels B, 2015, 'Relative misclassification (RM) of new medicine users based on look-back period', presented at Australian Population Health Congress, 07 September 2015 - 09 September 2015

Peng J; Liu JJ; Daniels B; Firriolo J; Laaksonen MA; Hawkins NJ; Meagher AP; Hayes I; Croxford M; Cai S; Ward RL, 2014, 'RETROSPECTIVE COMPARISON OF RECTAL CANCER TREATMENT IN CHINA AND AUSTRALIA FROM 1995-2012', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 10, pp. 106 - 106, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Daniels B; Ward R; Pearson S-A, 2013, 'DO PHARMACEUTICAL CLAIMS ACCURATELY REFLECT ONCOLOGY PRESCRIBING PRACTICE: EVIDENCE FROM AN AUSTRALIAN HER2+EARLY BREAST CANCER COHORT (HER2EBC)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 9, pp. 123 - 123, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Srasuebkul P; Ward R, 2013, 'HER2 POSITIVE EARLY BREAST CANCER (HER2EBC): AN AUSTRALIAN PATTERN OF CARE STUDY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 9, pp. 81 - 81, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B, 2012, 'Building chemotherapy protocols: linking dispensing and administration records from the Elements of Cancer Care study', Adelaide, SA, presented at Australian Population Health Congress, Adelaide, SA, 10 September 2012 - 12 September 2012